AHRQ Singles Out “Priority Conditions” For Comparing Drug Effectiveness
This article was originally published in The Pink Sheet Daily
Executive Summary
The Agency for Healthcare Research & Quality will conduct comparative research on drugs used for 10 of the top conditions affecting Medicare beneficiaries, including ischemic heart disease, asthma and stroke. AHRQ will use the $15 mil. provided in the fiscal year 2005 omnibus appropriations bill.
You may also be interested in...
Medicare Part D Benefit Pegged At $53.6 Bil. For 2006 By House Panel
The amount matches the estimate in the Administration’s budget request for the first nine months of the Rx drug benefit. A vote on the House Appropriations subcommittee’s mark by the full committee is slated for June 15, but may be rescheduled for June 16.
Medicare Part D Benefit Pegged At $53.6 Bil. For 2006 By House Panel
The amount matches the estimate in the Administration’s budget request for the first nine months of the Rx drug benefit. A vote on the House Appropriations subcommittee’s mark by the full committee is slated for June 15, but may be rescheduled for June 16.
Comparative Effectiveness Study Proposals Requested By AHRQ
AHRQ is asking CERTs for proposals to conduct short-term research programs examining existing data on the 10 priority areas the agency has identified. The research is part of AHRQ’s mandate under the Medicare Modernization Act.